Russian Direct Investment Fund

What Russian Direct Investment Fund does

The Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund, established in 2011 by presidential initiative under the Government of the Russian Federation and headquartered in Moscow. The fund operates a co-investment model in which RDIF anchors transactions alongside leading international institutional investors, sovereign wealth funds, and strategic corporate partners, with automatic participation mechanisms for established partners and the ability to hold up to 50% of share capital in individual deals. Over 2.4 trillion rubles have been invested across more than 100 projects in the Russian economy through 2026, supplemented by over 1.9 trillion rubles in co-investor and partner capital, with portfolio companies collectively generating revenue equivalent to 10% of Russian GDP and employing over 1.5 million people. RDIF's distribution model is built on bilateral and multilateral relationships with sovereign wealth funds in the UAE (Mubadala), Saudi Arabia (PIF), Qatar (QIA), China (CIC), and Indonesia (Danantara), combined with international economic forums (notably the St. Petersburg International Economic Forum) and bilateral government summits as primary go-to-market channels.

RDIF's core operating subsidiaries include RDIF Technologies (innovation investment channel), RDIF Healthcare (healthcare focus area), and the integrated RVC (Russian Venture Company). The fund operates a portfolio of proprietary healthcare products developed through co-investment and partnership with Russian research institutes, most prominently the Sputnik V COVID-19 vaccine (the world's first registered COVID-19 vaccine, 91.6% efficacy in Phase III trials, 97.6% real-world efficacy), Sputnik Light single-component vaccine, Avifavir COVID-19 treatment drug (first registered Favipiravir-based COVID-19 drug), and EMG diagnostic test systems — collectively deployed across 70+ countries via 25 production sites in 15 countries. RDIF does not operate consumer pricing or traditional revenue generation; returns are derived from investment exits, dividends, and capital appreciation across portfolio companies, with co-investment economics negotiated individually with each partner. CEO Kirill Dmitriev leads the fund and concurrently serves as Special Representative of the President of Russia for Investment and Economic Cooperation, reflecting RDIF's role as Russia's primary investment diplomacy instrument.

Name

Russian Direct Investment Fund

Legal name

JSC Management Company of the Russian Direct Investment Fund (JSC "Management Company RDIF")

Website

https://rdif.ru

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

101–250 employees

Short description

RDIF is Russia's state-owned sovereign wealth fund, established in 2011, that co-invests with international sovereign wealth funds and strategic partners across the Russian economy. It has deployed over 2.4 trillion rubles in 100+ projects and built a global healthcare portfolio including the Sputnik V vaccine.

Ownership category

akta.pro rank

Product category

Sovereign Wealth Fund Management

NAICS

Funds, Trusts, and Other Financial Vehicles (525)

SIC

Investment Advice (6282)

akta.pro primary industry

Regional Development Banks (BPADACAB)

Keywords

• Sovereign wealth fund
• Direct investment co-investment
• Private equity Russia
• Infrastructure investment
• Venture capital Russia

Headquarters

HQ city

Moscow

HQ country

Russia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Investment Returns: RDIF generates returns through co-investments in Russian companies across various sectors including energy, infrastructure, IT, and healthcare. Returns come from dividends, capital appreciation, and exit proceeds when portfolio companies are sold or listed publicly.
2. Co-investment Model: The fund co-invests alongside international partners, with automatic co-investment mechanisms where certain partners participate in all fund deals. RDIF may own up to 50% of share capital, with consortium shares potentially exceeding 50%.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

RDIF is Russia's sovereign wealth fund that co-invests alongside leading international investors in Russian companies across sectors including energy, infrastructure, IT, and healthcare. It operates joint investment platforms with global sovereign wealth funds (Mubadala, PIF, QIA, CIC, Danantara) and manages RDIF Technologies and RDIF.Healthcare as dedicated investment verticals. In addition, RDIF has served as the international vehicle for Russia's COVID-19 response portfolio, including the Sputnik V vaccine, Sputnik Light booster, Avifavir antiviral, and EMG diagnostic test system.

Product overview

RDIF operates as Russia's sovereign wealth fund offering a portfolio of investment products and healthcare initiatives. The core investment offering includes co-investment mechanisms with international partners, while the healthcare division manages COVID-19 related products including the Sputnik V and Sputnik Light vaccines, Avifavir treatment drug, and EMG diagnostic test systems. RDIF Technologies serves as the investment channel for innovative Russian technology companies, and RDIF.Healthcare represents the strategic healthcare investment focus area.

Differentiator

Problem solved

Functional benefit

Brands

• RDIF Healthcare: Strategic investment focus on healthcare sector projects
• RDIF Technologies

Products and services

• Sputnik V COVID-19 Vaccine COVID-19 vaccine based on a human adenovirus vector platform, developed by the Gamaleya Research Centre and promoted internationally by RDIF; demonstrated 91.6% efficacy in Phase III clinical trials published in The Lancet and 97.6% efficacy in real-world data from 3.8 million vaccinated Russians; approved in over 70 countries.
• Sputnik Light COVID-19 Vaccine Single-component adenovirus vector COVID-19 vaccine with over 80% efficacy against infection, designed as a booster and for revaccination after other vaccines; registered in over 20 countries.
• Avifavir COVID-19 Treatment Drug Russia's first registered COVID-19 antiviral drug and the world's first Favipiravir-based therapy approved for coronavirus patients; halves the disease term compared to standard therapy; supplied to 74 regions in Russia and 17 countries, with production exceeding 600,000 packs per month at 3 sites.
• EMG COVID-19 Diagnostic Test System Rapid mobile COVID-19 diagnostic test system adapted for both in-house laboratories and portable minilabs deployable in hospitals, schools, offices, airports and railway stations; over 17 million tests delivered to international markets.
• RDIF Co-Investment Platform Sovereign wealth fund co-investment platform structuring direct deals alongside leading international investors, sovereign wealth funds, and strategic partners in Russian companies across energy, infrastructure, IT, and healthcare; features automatic co-investment mechanisms for established partners and consortium shares potentially exceeding 50%.
• RDIF Technologies Investment Vertical Investment channel within RDIF dedicated to attracting foreign investment into innovative Russian technology companies, supporting technological development as part of RDIF's strategic investment priorities; operates an alliance with leading Russian AI technology companies.
• RDIF Healthcare Investment Vertical Strategic investment vertical within RDIF focused on healthcare sector projects, building on COVID-19 response activities (Sputnik V, Sputnik Light, Avifavir, EMG) and prior medical and health protection investments aimed at improving quality of life.
• RDIF Regional Projects Platform Russia's only dedicated platform providing leading global investors with access to regional investment projects across Russian regions, including infrastructure, social, and economic development opportunities.

Quantifiable outcome

• Over 2.4 trillion rubles invested in Russian economy since inception
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered major and core.

• Roscongress FoundationmajorGTM or Marketing Partner · 1 January 2025Foundation organizing St. Petersburg Economic Forum and other events; central to RDIF's cooperation with Middle Eastern businesses.
• Dr. Reddy's LaboratoriescoreChannel Partner/ Reseller/ Distributor · 1 May 2021Indian pharmaceutical company serves as local distribution partner for Sputnik V vaccine in India, coordinating expansion across multiple cities.
• Gamaleya Research CentrecoreStrategic or Co-development Partner · 1 January 2020Russian research institute that developed Sputnik V and Sputnik Light vaccines; RDIF coordinated production and international promotion.
• ChemRar GroupmajorStrategic or Co-development Partner · 1 January 2020Russian pharmaceutical group partnered with RDIF to produce Avifavir, Russia's first registered COVID-19 treatment drug.
• RVC (Russian Venture Company)majorStrategic or Co-development Partner · 1 January 2011State development institution integrated into RDIF structure, focusing on venture capital market development and technological innovation.

Scale indicators9 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Mubadala Investment Company: UAE sovereign wealth fund and one of RDIF's closest co-investment partners with established joint platforms. Operates a similar direct-investment, co-investment model across global markets, making it the most directly comparable peer.
• Public Investment Fund (PIF): Saudi Arabia's sovereign wealth fund and a core RDIF partner on joint investment platforms. Comparable mandate to deploy national capital via direct stakes and partnerships across sectors and geographies.
• Qatar Investment Authority: Qatar's sovereign wealth fund with multi-decade co-investment relationship with RDIF. Similar state-owned direct-investment mandate targeting global assets and partnerships.
• China Investment Corporation (CIC): China's sovereign wealth fund and recent RDIF/Danantara co-investor committing US$500M each. Operates as China's primary state-owned direct investor, with comparable scale and cross-border mandate.
• Temasek Holdings: Singapore state-owned investment company with global direct-investment portfolio. Comparable in operating as a long-term, government-linked direct investor with diversified sector exposure.
• GIC Private Limited: Singapore's sovereign wealth fund managing the country's foreign reserves via direct and fund investments globally. Similar government-mandated, long-horizon capital allocation model.
• Abu Dhabi Investment Authority (ADIA): UAE's largest sovereign wealth fund investing globally across asset classes. Operates a comparable state-owned long-term capital allocation model with co-investment relationships in the Gulf.
• Indonesia Investment Authority (Danantara): Indonesia's sovereign wealth fund and recent RDIF joint-platform partner. Direct peer given shared state-owned mandate to channel national capital into strategic investments and partnerships.
• Korea Investment Corporation (KIC): South Korea's sovereign wealth fund managing public pension reserves through global direct and indirect investments. Operates a similar state-mandated cross-border investment function to RDIF.
• Khazanah Nasional: Malaysia's sovereign wealth fund with strategic investment and co-investment mandate. Comparable as a state-owned investor actively deploying capital into domestic and international partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/rdif_press
• YouTubeyoutube.com/channel/UCLvQuKL3Nn7NnT9Jyi_dlgQ
• Facebookfacebook.com/rdifru
• LinkedInlinkedin.com/company/2648346

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments31 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Russian Direct Investment Fund